StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) shareholders

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)

Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%

Ownership

Who owns Latigo Biotherapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $5.04M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Dr. Beth C. Seidenberg
Joint filing with Westlake BioPartners Fund I, L.P. (9.00%), Westlake BioPartners GP I, LLC (9.00%) and 2 more
13,199,66919.90%13G (passive)Sep 30, 2026
James B. Tananbaum
Joint filing with Foresite Capital Fund V, L.P. (5.60%), Foresite Capital Management V, LLC (5.60%) and 2 more
9,181,32814.50%13D (active)Aug 10, 2026
RA Capital Healthcare Fund, L.P.
Joint filing with RA Capital Management, L.P. (8.40%), Peter Kolchinsky (8.40%) and 1 more
5,295,6908.40%13G (passive)Aug 10, 2026
Deep Track Capital, LP
Joint filing with Deep Track Biotechnology Master Fund, Ltd. (7.03%), David Kroin (7.03%)
4,446,6567.03%13G (passive)Aug 7, 2026
AI Biotechnology LLC
Joint filing with Access Industries Holdings LLC (5.00%), Access Industries Management, LLC (5.00%) and 1 more
3,185,1775.00%13G (passive)Aug 11, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Nima FarzanPresident and CEO, Director114,4530.17%Aug 6, 2026
Neha KrishnamohanCFO and Chief Business Officer––Aug 6, 2026
Neil SinglaChief Medical Officer––Aug 6, 2026
Todd N. SmithDirector––Aug 10, 2026
Beth C. SeidenbergDirector, 10% owner4,916,3747.42%Aug 10, 2026
James B. TananbaumDirector, 10% owner3,117,6644.70%Aug 10, 2026
Timothy P. WalbertDirector––Aug 6, 2026
Sara BonsteinDirector––Aug 6, 2026
Kevin RaidyDirector––Aug 6, 2026
5AM Opportunities II (GP), LLC10% owner––Aug 12, 2026
5AM Opportunities II, L.P.10% owner––Aug 12, 2026
Sanofi10% owner672,7881.01%Aug 12, 2026
Andrew J. Schwab10% owner––Aug 12, 2026
Kush Parmar10% owner––Aug 12, 2026
5AM Partners VI, LLC10% owner7,325,96211.05%Aug 12, 2026
5AM Ventures VI, L.P.10% owner––Aug 12, 2026
Westlake BioPartners GP II, LLC10% owner27,9560.04%Aug 11, 2026
Westlake BioPartners Opportunity Fund I, L.P.10% owner––Aug 11, 2026
Westlake BioPartners Opportunity GP I, LLC10% owner––Aug 11, 2026
Westlake BioPartners Fund II, L.P.10% owner––Aug 11, 2026
Westlake BioPartners Fund I, L.P.10% owner––Aug 11, 2026
Westlake BioPartners GP I, LLC10% owner4,995,3287.53%Aug 11, 2026
Capital Fund VI LP Foresite10% owner3,414,5445.15%Aug 10, 2026
Foresite Capital Fund V, L.P.10% owner––Aug 10, 2026
Capital Management VI LLC Foresite10% owner––Aug 10, 2026
Foresite Capital Management V, LLC10% owner––Aug 10, 2026
Foresite Capital Opportunity Management V, LLC10% owner––Aug 10, 2026
Foresite Capital Opportunity Fund V, L.P.10% owner––Aug 10, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
5AM Partners VI, LLC
10% owner
Aug 10, 2026Conversion+4,975,543––4,975,543
5AM Partners VI, LLC
10% owner
Aug 10, 2026Conversion+2,350,419––2,350,419
Sanofi
10% owner
Aug 10, 2026Conversion+177,978––672,788
Sanofi
10% owner
Aug 10, 2026Conversion+494,800––494,800
Westlake BioPartners GP I, LLC
10% owner
Aug 10, 2026Conversion+1,484,401––4,995,328
Westlake BioPartners GP I, LLC
10% owner
Aug 10, 2026Conversion+3,464,072––3,510,927
Westlake BioPartners GP I, LLC
10% owner
Aug 10, 2026Conversion+1,027,635––5,944,009
Westlake BioPartners GP I, LLC
10% owner
Aug 10, 2026Conversion+165,519––5,160,847
Westlake BioPartners GP I, LLC
10% owner
Aug 10, 2026Conversion+2,066,857––2,094,813
Westlake BioPartners GP I, LLC
10% owner
Aug 10, 2026Conversion+3,547,842––4,916,374
Westlake BioPartners GP I, LLC
10% owner
Aug 10, 2026Conversion+938,979––1,368,532
Beth C. Seidenberg
Director, 10% owner
Aug 10, 2026Conversion+3,547,842––4,916,374
Beth C. Seidenberg
Director, 10% owner
Aug 10, 2026Conversion+938,979––1,368,532
Beth C. Seidenberg
Director, 10% owner
Aug 10, 2026Conversion+1,027,635––5,944,009
Beth C. Seidenberg
Director, 10% owner
Aug 10, 2026Conversion+3,464,072––3,510,927
Beth C. Seidenberg
Director, 10% owner
Aug 10, 2026Conversion+1,484,401––4,995,328
Beth C. Seidenberg
Director, 10% owner
Aug 10, 2026Conversion+165,519––5,160,847
Beth C. Seidenberg
Director, 10% owner
Aug 10, 2026Conversion+2,066,857––2,094,813
Capital Fund VI LP Foresite
10% owner
Aug 10, 2026Conversion+296,880––3,414,544
Capital Fund VI LP Foresite
10% owner
Aug 10, 2026Conversion+3,117,664––3,117,664
Capital Fund VI LP Foresite
10% owner
Aug 10, 2026Conversion+3,117,664––3,117,664
Capital Fund VI LP Foresite
10% owner
Aug 10, 2026Conversion+445,320––3,562,984
Capital Fund VI LP Foresite
10% owner
Aug 10, 2026Conversion+1,125,823––1,125,823
Capital Fund VI LP Foresite
10% owner
Aug 10, 2026Conversion+742,201––1,868,024
Capital Fund VI LP Foresite
10% owner
Aug 10, 2026Buy+140,000$18.00$2.52M2,008,024
Capital Fund VI LP Foresite
10% owner
Aug 10, 2026Conversion+195,776––2,203,800
James B. Tananbaum
Director, 10% owner
Aug 10, 2026Conversion+3,117,664––3,117,664
James B. Tananbaum
Director, 10% owner
Aug 10, 2026Conversion+445,320––3,562,984
James B. Tananbaum
Director, 10% owner
Aug 10, 2026Conversion+296,880––3,414,544
James B. Tananbaum
Director, 10% owner
Aug 10, 2026Conversion+1,125,823––1,125,823
James B. Tananbaum
Director, 10% owner
Aug 10, 2026Conversion+742,201––1,868,024
James B. Tananbaum
Director, 10% owner
Aug 10, 2026Buy+140,000$18.00$2.52M2,008,024
James B. Tananbaum
Director, 10% owner
Aug 10, 2026Conversion+195,776––2,203,800
James B. Tananbaum
Director, 10% owner
Aug 10, 2026Conversion+3,117,664––3,117,664

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
2.63%
1M shares short
Days to cover
5.4
At 0M shares a day
Change since last report
+19.8%
From 1M shares
Short volume, 20 days
47.4%
Of volume reported to FINRA

Shares sold short, last 3 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Latigo Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 15,626 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?